|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM336517874 |
| 003 |
DE-627 |
| 005 |
20231225232325.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2022 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202110618
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1121.xml
|
| 035 |
|
|
|a (DE-627)NLM336517874
|
| 035 |
|
|
|a (NLM)35119139
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Xie, Ruosen
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a pH-Responsive Polymer Nanoparticles for Efficient Delivery of Cas9 Ribonucleoprotein With or Without Donor DNA
|
| 264 |
|
1 |
|c 2022
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 10.06.2022
|
| 500 |
|
|
|a Date Revised 05.11.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2022 Wiley-VCH GmbH.
|
| 520 |
|
|
|a Clustered regularly interspaced short palindromic repeat (CRISPR)-associated protein 9 (Cas9) may offer new therapeutics for genetic diseases through gene disruption via nonhomologous end joining (NHEJ) or gene correction via homology-directed repair (HDR). However, clinical translation of CRISPR technology is limited by the lack of safe and efficient delivery systems. Here, facilely fabricated pH-responsive polymer nanoparticles capable of safely and efficiently delivering Cas9 ribonucleoprotein alone (termed NHEJ-NP, diameter = 29.4 nm), or together with donor DNA (termed HDR-NP, diameter = 33.3 nm) are reported. Moreover, intravenously, intratracheally, and intramuscularly injected NHEJ-NP induces efficient gene editing in mouse liver, lung, and skeletal muscle, respectively. Intramuscularly injected HDR-NP also leads to muscle strength recovery in a Duchenne muscular dystrophy mouse model. NHEJ-NP and HDR-NP possess many desirable properties including high payload loading content, small and uniform sizes, high editing efficiency, good biocompatibility, low immunogenicity, and ease of production, storage, and transport, making them great interest for various genome editing applications with clinical potentials
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a CRISPR-Cas9
|
| 650 |
|
4 |
|a genome editing
|
| 650 |
|
4 |
|a nanomedicine
|
| 650 |
|
7 |
|a Polymers
|2 NLM
|
| 650 |
|
7 |
|a Ribonucleoproteins
|2 NLM
|
| 650 |
|
7 |
|a DNA
|2 NLM
|
| 650 |
|
7 |
|a 9007-49-2
|2 NLM
|
| 700 |
1 |
|
|a Wang, Xiuxiu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Yuyuan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ye, Mingzhou
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhao, Yi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yandell, Brian S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gong, Shaoqin
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 34(2022), 23 vom: 11. Juni, Seite e2110618
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:34
|g year:2022
|g number:23
|g day:11
|g month:06
|g pages:e2110618
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202110618
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 34
|j 2022
|e 23
|b 11
|c 06
|h e2110618
|